January 20, 2015
by Bradley McAllister
The US Supreme Court ruled 7-2 Tuesday that appellate review of factual matters in a patent dispute must apply the clear error standard of review, not a de novo standard. In Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., the court held that the US Court of Appeals for the Federal Circuit was ...[read more]
October 16, 2014
by Bradley McAllister
The US Supreme Court heard oral arguments on Wednesday in two cases fraught with procedural issues. In Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. the court must decide whether to allow the US Court of Appeals for the Federal Circuit to continue to qualify every issue bearing on the scope of an ...[read more]
April 19, 2014
by Matthew Pomy
US Supreme Court Chief Justice John Roberts denied the request of Teva Pharmaceuticals USA for a stay on the lower court ruling. The appeals court's ruling made Teva's Copaxone drug available to be produced in a generic form. Teva sought to have this delayed until the Supreme Court is able to ...[read more]
March 31, 2014
by Addison Morris
The US Supreme Court on Monday granted certiorari in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. to determine how the US Court of Appeals for the Federal Circuit is to interpret claims in a patent appeal. Federal appeals courts traditionally review a district court's conclusion only to ...[read more]
March 5, 2014
by Endia Vereen
JURIST Guest Columnist Tara Pakrouh, Widener University School of Law Class of 2015, discusses Merck & Co.'s $100 million settlement concerning the corporation's NuvaRing contraceptive device, the board's liability and the fiduciary duties it owes to its shareholders...In a December 2000 email ...[read more]
November 23, 2013
by Matthew Pomy
The Supreme Court of Canada on Friday upheld a ban on pharmacies selling their own generic drug brands. The ruling addresses the Drug Interchangeability and Dispensing Fee Act and the Ontario Drug Benefit Act which were meant to control the rising price of pharmaceuticals. Under this scheme, ...[read more]
June 17, 2013
by Jaclyn Belczyk
The US Supreme Court ruled 5-3 Monday in Federal Trade Commission v. Actavis that reverse payment settlements can sometimes violate antitrust laws. A reverse payment settlement, better known as a "pay to delay" settlement, is an agreement in which a patent holder pays a competitor to delay them ...[read more]
March 4, 2008
by Leslie Schulman
A federal judge Tuesday dismissed a lawsuit brought by the Association of American Physicians and Surgeons (AAPS) against the US Food and Drug Administration (FDA) and Barr Pharmaceuticals seeking to overturn the FDA's 2006 decision to approve the over-the-counter sale of so-called... ...[read more]
August 16, 2007
by Bernard Hibbitts
Eric Linge, Pitt Law '09, files from Mumbai:The cruel irony is that the most pressing diseases are the ones that don't make money. Multinational pharmaceutical corporations from the United States and Europe can rake in the profits selling drugs that treat rich world diseases like diabetes, ...[read more]
February 15, 2007
by Brett Murphy
The Internal Revenue Service (IRS) and drug manufacturer Merck Pharmaceuticals reached a $2.3 billion agreement on Wednesday that will settle all outstanding tax disputes from 1993 to 2006. According to an IRS statement, the settlement, one of the largest in recent history, resolves federal taxes, ...[read more]

Support JURIST

We rely on our readers to keep JURIST running

 Donate now!

© Copyright JURIST Legal News and Research Services, Inc., 2013.